Action as in trial updates? That would be disappointing.
I won't be stoked if they do a placement to sophs before announcing cohort 3 interim data. Unless they are sitting on it because it's not very good news?
At current MC, to raise only 2 quarters of funding would be a 20% dilution (plus probably more options handed out). The diution compounds over the years.
I'm really surprised the MC has got so low. I suppose many investors are aware of how expensive cellular therapies, in particular, are to develop. Which may put some big investors off.
CHM Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)